Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 7;12(6):601.
doi: 10.3390/healthcare12060601.

Successful Desensitization to Sorafenib and Imatinib-A Report of Two Cases and a Literature Review

Natasa Kusic  1 , Vesna Tomic Spiric  1   2 , Snezana Arandjelovic  1   2 , Aleksandra Peric Popadic  1   2 , Ivana Bozic Antic  3   4 , Milan Dimitrijevic  1 , Rada Miskovic  1   2 , Ljiljana Stefanovic  1 , Aleksandra Plavsic  1   2
Affiliations
Case Reports

Successful Desensitization to Sorafenib and Imatinib-A Report of Two Cases and a Literature Review

Natasa Kusic et al. Healthcare (Basel). .

Abstract

Background: Drug desensitization allows for safe administration of a drug to a patient with a previous hypersensitivity reaction. Successful desensitization protocols have been described for different medications, including protocols for oncology patients. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far.

Objective: The objective of this paper is to describe the process of the sorafenib and imatinib drug hypersensitivity diagnosis and desensitization process in two patients.

Methods: Two oncology patients who experienced non-immediate hypersensitivity reactions to sorafenib and imatinib underwent desensitization to these drugs. We designed a protocol for the first patient and used a modified protocol from the literature for the second patient.

Results: By using a slow desensitization technique and gradual tapering of corticosteroids and antihistamines, both patients reached the target dose of the incriminated drug.

Conclusions: Desensitization to sorafenib and imatinib can be an effective therapeutic option in patients with hypersensitivity to those medications, without alternative treatment options.

Keywords: desensitization; drug hypersensitivity reaction; imatinib; sorafenib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

    1. Muraro A., Lemanske R.F., Jr., Castells M., Torres M.J., Khan D., Simon H.-U., Bindslev-Jensen C., Burks W., Poulsen L.K., Sampson H.A., et al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 2017;72:1006–1021. doi: 10.1111/all.13132. - DOI - PubMed
    1. Scherer K., Brockow K., Aberer W., Gooi J.H.C., Demoly P., Romano A., Schnyder B., Whitaker P., Cernadas J.S.R., Bircher A.J., et al. Desensitization in delayed drug hypersensitivity reactions—An EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68:844–852. doi: 10.1111/all.12161. - DOI - PubMed
    1. Cernadas J.R., Brockow K., Romano A., Aberer W., Torres M.J., Bircher A., Campi P., Sanz M.L., Castells M., Demoly P., et al. General considerations on rapid desensitization for drug hypersensitivity—A consensus statement. Allergy. 2010;65:1357–1366. doi: 10.1111/j.1398-9995.2010.02441.x. - DOI - PubMed
    1. De Las Vecillas Sánchez L., Alenazy L.A., Garcia-Neuer M., Castells M.C. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Int. J. Mol. Sci. 2017;18:1316. doi: 10.3390/ijms18061316. - DOI - PMC - PubMed
    1. Linauskiene K., Malinauskiene L., Vitkauskaite E., Chomiciene A., Blaziene A. Severe adverse skin reaction and desensitization to sorafenib. Ann. Allergy Asthma Immunol. 2016;117:209–210. doi: 10.1016/j.anai.2016.06.013. - DOI - PubMed

Publication types

LinkOut - more resources